Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2025)
Haleon (HLN) posted Liabilities and Shareholders Equity of $43.4 billion for Q4 2025, down 1.45% on a QoQ basis from $44.0 billion in Q4 2024, and down 1.45% year-over-year from $44.0 billion in Q4 2024.
Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends
Haleon's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $43.4 billion for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 1.45% year-over-year to $43.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $171.9 billion (changed 0.38% YoY) and the FY2025 annual result came in at $43.0 billion, down 1.92% from the prior year.
- Liabilities and Shareholders Equity was $43.4 billion for Q4 2025 at Haleon, down from $44.0 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $56.7 billion in Q2 2022 and bottomed at $40.8 billion in Q4 2022.
- A 5-year average of $44.8 billion and a median of $43.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slipped 24.57% — and 2024, when it rose 4.2%.
- Haleon's Liabilities and Shareholders Equity stood at $46.4 billion in 2021, then declined by 12.07% to $40.8 billion in 2022, then increased by 3.51% to $42.3 billion in 2023, then climbed by 4.2% to $44.0 billion in 2024, then slipped by 1.45% to $43.4 billion in 2025.
- Business Quant data shows HLN's Liabilities and Shareholders Equity at $43.4 billion in Q4 2025, $44.0 billion in Q4 2024, and $42.2 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 6.71 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 25.35 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 928.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.40 Bn |
| Dec 31, 2024 | 44.04 Bn |
| Jun 30, 2024 | 42.15 Bn |
| Dec 31, 2023 | 42.27 Bn |
| Jun 30, 2023 | 42.75 Bn |
| Dec 31, 2022 | 40.84 Bn |
| Jun 30, 2022 | 56.68 Bn |
| Dec 31, 2021 | 46.44 Bn |